# Selecta Biosciences Inc. (SELB)

Source: https://www.quantisnow.com/company/SELB
Generated: 2026-11-18T14:02:37.201Z

- Ticker: SELB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2016
- Website: selectabio.com

## About

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

## Latest SELB news and filings

- 2024-02-14 22:27 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Selecta Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-selecta-biosciences-inc-5265186)
- 2024-02-14 21:42 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Selecta Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-selecta-biosciences-inc-5264322)
- 2024-02-14 17:38 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-selecta-biosciences-inc-amendment-5261521)
- 2024-02-09 22:13 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-selecta-biosciences-inc-amendment-5247243)
- 2024-02-09 13:50 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Selecta Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-selecta-biosciences-inc-5243978)
- 2024-01-31 21:30 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Selecta Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-selecta-biosciences-inc-5220801)
- 2024-01-23 21:05 UTC [SEC Form 8-K] [Selecta Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)](https://www.quantisnow.com/insight/selecta-biosciences-inc-filed-sec-form-8-k-financial-statements-and-5201714)
- 2024-01-19 21:12 UTC [SEC Form 8-K] [Selecta Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/selecta-biosciences-inc-filed-sec-form-8-k-notice-of-delisting-5196425)
- 2024-01-12 21:16 UTC [SEC Form S-8] [SEC Form S-8 filed by Selecta Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-selecta-biosciences-inc-5186046)
- 2024-01-08 13:45 UTC [SEC Form 8-K] [Selecta Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/selecta-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-5175341)
- 2024-01-08 12:10 UTC [Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity](https://www.quantisnow.com/insight/cartesian-therapeutics-highlights-progress-and-2024-strategic-priorities-across-innovative-5174627)
- 2024-01-08 12:00 UTC [Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis](https://www.quantisnow.com/insight/cartesian-therapeutics-announces-positive-long-term-follow-up-data-from-phase-2a-5174456)
- 2024-01-04 22:12 UTC [SEC Form 4] [Singer Michael was granted 178,000 units of Common  Stock, increasing direct ownership by 162% to 288,123 units (SEC Form 4)](https://www.quantisnow.com/insight/singer-michael-was-granted-178000-units-of-common-stock-increasing-5170759)
- 2024-01-04 22:08 UTC [SEC Form 4] [Davis Blaine was granted 2,424,000 units of Common  Stock (SEC Form 4)](https://www.quantisnow.com/insight/davis-blaine-was-granted-2424000-units-of-common-stock-sec-5170720)
- 2024-01-04 22:08 UTC [SEC Form 4] [Jewell Christopher M was granted 778,200 units of Common  Stock (SEC Form 4)](https://www.quantisnow.com/insight/jewell-christopher-m-was-granted-778200-units-of-common-stock-5170712)
- 2024-01-04 22:07 UTC [SEC Form 4] [Brunn Carsten was granted 4,654,100 shares, increasing direct ownership by 1,777% to 4,916,056 units (SEC Form 4)](https://www.quantisnow.com/insight/brunn-carsten-was-granted-4654100-shares-increasing-direct-ownership-by-5170702)
- 2024-01-04 22:07 UTC [SEC Form 4] [Sallin Aymeric was granted 178,000 units of Common  Stock (SEC Form 4)](https://www.quantisnow.com/insight/sallin-aymeric-was-granted-178000-units-of-common-stock-sec-5170699)
- 2024-01-04 22:06 UTC [SEC Form 4] [Barabe Timothy C was granted 178,000 shares, increasing direct ownership by 71% to 428,013 units (SEC Form 4)](https://www.quantisnow.com/insight/barabe-timothy-c-was-granted-178000-shares-increasing-direct-ownership-5170694)
- 2024-01-04 22:06 UTC [SEC Form 4] [Springer Timothy A was granted 178,000 shares, increasing direct ownership by 2% to 7,471,625 units (SEC Form 4)](https://www.quantisnow.com/insight/springer-timothy-a-was-granted-178000-shares-increasing-direct-ownership-5170692)
- 2024-01-04 22:06 UTC [SEC Form 4] [Miljkovic Milos was granted 548,200 units of Common  Stock (SEC Form 4)](https://www.quantisnow.com/insight/miljkovic-milos-was-granted-548200-units-of-common-stock-sec-5170686)
- 2024-01-04 22:05 UTC [SEC Form 4] [Desilva Nishan M was granted 178,000 shares, increasing direct ownership by 2,543% to 185,000 units (SEC Form 4)](https://www.quantisnow.com/insight/desilva-nishan-m-was-granted-178000-shares-increasing-direct-ownership-5170677)
- 2024-01-04 22:05 UTC [SEC Form 4] [Cox Carrie Smith was granted 178,000 shares, increasing direct ownership by 84% to 390,881 units (SEC Form 4)](https://www.quantisnow.com/insight/cox-carrie-smith-was-granted-178000-shares-increasing-direct-ownership-5170674)
- 2024-01-04 22:04 UTC [SEC Form 4] [Zenner Patrick J was granted 178,000 shares, increasing direct ownership by 322% to 233,248 units (SEC Form 4)](https://www.quantisnow.com/insight/zenner-patrick-j-was-granted-178000-shares-increasing-direct-ownership-5170660)
- 2024-01-04 22:04 UTC [SEC Form 4] [Kalayoglu Murat was granted 178,000 units of Common  Stock, increasing direct ownership by 69% to 435,739 units (SEC Form 4)](https://www.quantisnow.com/insight/kalayoglu-murat-was-granted-178000-units-of-common-stock-increasing-5170648)
- 2024-01-04 22:03 UTC [SEC Form 4] [Kurtoglu Metin was granted 1,531,000 units of Common  Stock (SEC Form 4)](https://www.quantisnow.com/insight/kurtoglu-metin-was-granted-1531000-units-of-common-stock-sec-5170647)
- 2023-12-08 21:28 UTC [SEC Form 8-A12G filed by Selecta Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-a12g-filed-by-selecta-biosciences-inc-5127802)
- 2023-12-04 21:39 UTC [SEC Form D] [SEC Form D/A filed by Selecta Biosciences Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-da-filed-by-selecta-biosciences-inc-amendment-5116973)
- 2023-12-04 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Selecta Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-selecta-biosciences-inc-5114910)
- 2023-12-01 21:43 UTC [SEC Form D] [SEC Form D filed by Selecta Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-selecta-biosciences-inc-5114233)
- 2023-12-01 13:31 UTC [SEC Form S-3] [SEC Form S-3/A filed by Selecta Biosciences Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-s-3a-filed-by-selecta-biosciences-inc-amendment-5112819)
- 2023-11-27 21:18 UTC [SEC Form 8-K] [Selecta Biosciences Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/selecta-biosciences-inc-filed-sec-form-8-k-leadership-update-5104516)
- 2023-11-22 21:39 UTC [SEC Schedule 13D] [SEC Form SC 13D filed by Selecta Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-sc-13d-filed-by-selecta-biosciences-inc-5101463)
- 2023-11-22 21:38 UTC [SEC Schedule 13D] [SEC Form SC 13D filed by Selecta Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-sc-13d-filed-by-selecta-biosciences-inc-5101459)
- 2023-11-17 14:51 UTC [SEC Form 3] [New insider Hoge Elizabeth claimed ownership of 3,561,438 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-hoge-elizabeth-claimed-ownership-of-3561438-shares-sec-5092281)
- 2023-11-17 13:15 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Selecta Biosciences Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-selecta-biosciences-inc-amendment-5092025)
- 2023-11-15 22:26 UTC [SEC Form 4] [SEC Form 4 filed by Davis Blaine](https://www.quantisnow.com/insight/sec-form-4-filed-by-davis-blaine-5088293)
- 2023-11-15 22:26 UTC [SEC Form 4] [Brunn Carsten returned $1,073,518 worth of shares to the company (521,125 units at $2.06), decreasing direct ownership by 67% to 261,956 units (SEC Form 4)](https://www.quantisnow.com/insight/brunn-carsten-returned-1073518-worth-of-shares-to-the-company-5088290)
- 2023-11-15 22:20 UTC [SEC Form 4] [Springer Timothy A was granted 148,710 units of Series A Convertible Preferred Stock (SEC Form 4)](https://www.quantisnow.com/insight/springer-timothy-a-was-granted-148710-units-of-series-a-5088258)
- 2023-11-15 22:18 UTC [SEC Form 4] [SEC Form 4 filed by Desilva Nishan M](https://www.quantisnow.com/insight/sec-form-4-filed-by-desilva-nishan-m-5088251)
- 2023-11-15 22:18 UTC [SEC Form 4] [SEC Form 4 filed by Zenner Patrick J](https://www.quantisnow.com/insight/sec-form-4-filed-by-zenner-patrick-j-5088248)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SELB
- Earnings history: https://www.quantisnow.com/earnings/SELB
- Dividend history: https://www.quantisnow.com/dividends/SELB
- Insider transactions: https://www.quantisnow.com/insiders/SELB
- Options chain: https://www.quantisnow.com/options/SELB
- SEC 8-K filings only: https://www.quantisnow.com/company/SELB/8-k
- RSS and alerts for SELB: https://www.quantisnow.com/docs/rss-feeds.md
